Dr. Vivek Sharma, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 189
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 34402
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uofl Health - Jewish Hospital and Mary & Elizabeth Hospital Louisville, KY
- Baptist Health Louisville Louisville, KY
- University of Louisville Hospital Louisville, KY
- Uofl Health - Shelbyville Hospital Shelbyville, KY
Medical groups
- University of Louisville Physicians Inc (1,445 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 189
- Services billed
- 552
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 501 | 152 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 41 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 22 | 22 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 14 | 13 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 14 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Louisville, KY | 78 |
| Eliquis (apixaban) Other prescribers in Louisville, KY | 40 |
| Prochlorperazine Maleate Other prescribers in Louisville, KY | 38 |
| Gabapentin Other prescribers in Louisville, KY | 30 |
| Creon (lipase/protease/amylase) Other prescribers in Louisville, KY | 30 |
| Mirtazapine Other prescribers in Louisville, KY | 30 |
| Dexamethasone Other prescribers in Louisville, KY | 28 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Louisville, KY | 23 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Louisville, KY | 23 |
| Potassium Chloride Other prescribers in Louisville, KY | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 190 payments worth $164,663 in total to this clinician.
| Genzyme Corporation | $87,005 |
|---|---|
| Novo Nordisk Inc | $43,476 |
| Pfizer Inc. | $27,333 |
| AstraZeneca Pharmaceuticals LP | $5,197 |
| Daiichi Sankyo Inc. | $305 |
| Genentech USA, Inc. | $258 |
| Merck Sharp & Dohme LLC | $186 |
| Astellas Pharma US Inc | $158 |
| Compensation for services other than consulting (speaking, faculty) | $136,458 |
|---|---|
| Travel and Lodging | $16,775 |
| Consulting Fee | $7,166 |
| Food and Beverage | $4,171 |
| Education | $93.53 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) CABLIVI · Hematology | $10,388 |
| Genzyme Corporation Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $10,388 |
| Genzyme Corporation Apr 5, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $10,388 |
| Genzyme Corporation May 23, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $10,388 |
| Genzyme Corporation Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) CABLIVI · Hematology | $8,726 |
| Novo Nordisk Inc Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) NovoSeven · Hemophilia | $6,714 |
| Novo Nordisk Inc Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,550 |
| Pfizer Inc. Oct 2, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $6,325 |
| Novo Nordisk Inc Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) Alhemo · Hemophilia | $5,731 |
| Novo Nordisk Inc Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Alhemo · Hemophilia | $5,404 |
All 75 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,909 |
| Genzyme Corporation Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,909 |
| Pfizer Inc. Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) HYMPAVZI · IMMUNOLOGY | $3,125 |
| Genzyme Corporation Nov 7, 2025 | Consulting Fee QFITLIA | $841 |
| Novo Nordisk Inc Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Alhemo · Hemophilia | $4,421 |
| AstraZeneca Pharmaceuticals LP Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,280 |
| Novo Nordisk Inc Oct 29, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Lexington, KY · in-kind | $749 |
| Novo Nordisk Inc Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) Alhemo · Hemophilia | $5,731 |
| Novo Nordisk Inc Oct 23, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Richmond, VA · in-kind | $550 |
| Novo Nordisk Inc Oct 23, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Richmond, VA · in-kind | $207 |
| AstraZeneca Pharmaceuticals LP Oct 23, 2025 | Travel and Lodging travel to Louisville, KY | $63.98 |
| Novo Nordisk Inc Oct 23, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Richmond, VA · in-kind | $40.31 |
| Pfizer Inc. Oct 16, 2025 | Travel and Lodging HYMPAVZI · IMMUNOLOGY · travel to Miami, FL · in-kind | $230 |
| Pfizer Inc. Oct 16, 2025 | Travel and Lodging HYMPAVZI · IMMUNOLOGY · travel to Miami, FL · in-kind | $60.06 |
| Pfizer Inc. Oct 16, 2025 | Travel and Lodging HYMPAVZI · IMMUNOLOGY · travel to Miami, FL · in-kind | $30.00 |
| Pfizer Inc. Oct 15, 2025 | Travel and Lodging HYMPAVZI · IMMUNOLOGY · travel to Cincinnati, OH · in-kind | $927 |
| Pfizer Inc. Oct 15, 2025 | Travel and Lodging HYMPAVZI · IMMUNOLOGY · travel to Miami, FL · in-kind | $708 |
| Pfizer Inc. Oct 10, 2025 | Compensation for services other than consulting (speaking, faculty) HYMPAVZI · IMMUNOLOGY | $4,250 |
| Pfizer Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) HYMPAVZI · IMMUNOLOGY | $4,625 |
| Pfizer Inc. Oct 2, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $6,325 |
| Pfizer Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) HYMPAVZI · IMMUNOLOGY | $40.00 |
| Pfizer Inc. Sep 23, 2025 | Travel and Lodging HYMPAVZI · IMMUNOLOGY · travel to Miami, FL · in-kind | $247 |
| Genzyme Corporation Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $1,662 |
| Novo Nordisk Inc Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) NovoSeven · Hemophilia | $6,714 |
| Novo Nordisk Inc Sep 16, 2025 | Travel and Lodging NovoSeven · Hemophilia · travel to Evansville, IN · in-kind | $902 |
| Genzyme Corporation Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $2,966 |
| Genzyme Corporation Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,966 |
| Genzyme Corporation Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) CABLIVI · Hematology | $10,388 |
| Genzyme Corporation Aug 28, 2025 | Travel and Lodging CABLIVI · Hematology · travel to Charleston, SC · in-kind | $705 |
| Genzyme Corporation Aug 28, 2025 | Travel and Lodging CABLIVI · Hematology · travel to Charleston, SC · in-kind | $509 |
| Genzyme Corporation Aug 28, 2025 | Travel and Lodging CABLIVI · Hematology · travel to Charleston, SC | $190 |
| Genzyme Corporation Aug 28, 2025 | Travel and Lodging CABLIVI · Hematology · travel to Charleston, SC · in-kind | $164 |
| Genzyme Corporation Aug 28, 2025 | Travel and Lodging CABLIVI · Hematology · travel to Charleston, SC | $26.00 |
| Pfizer Inc. Aug 26, 2025 | Compensation for services other than consulting (speaking, faculty) HYMPAVZI · IMMUNOLOGY | $3,125 |
| Novo Nordisk Inc Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,550 |
| Novo Nordisk Inc Aug 15, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $546 |
| Novo Nordisk Inc Aug 15, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $394 |
| Novo Nordisk Inc Aug 15, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $220 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
| Pfizer Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) HYMPAVZI · IMMUNOLOGY | $3,125 |
| AstraZeneca Pharmaceuticals LP Jun 19, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,640 |
| Novo Nordisk Inc Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $835 |
| Genzyme Corporation Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) CABLIVI · Hematology | $831 |
| Novo Nordisk Inc Jun 5, 2025 | Compensation for services other than consulting (speaking, faculty) Alhemo · Hemophilia | $5,404 |
| Novo Nordisk Inc Jun 5, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Birmingham, MI · in-kind | $1,451 |
| Novo Nordisk Inc Jun 5, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Birmingham, MI · in-kind | $655 |
| Novo Nordisk Inc Jun 5, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Birmingham, MI · in-kind | $198 |
| Novo Nordisk Inc Jun 3, 2025 | Compensation for services other than consulting (speaking, faculty) Alhemo · Hemophilia | $5,076 |
| Novo Nordisk Inc Jun 3, 2025 | Travel and Lodging Alhemo · Hemophilia · travel to Cincinnati, OH · in-kind | $753 |
| Genzyme Corporation May 23, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $10,388 |
| Genzyme Corporation May 23, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $3,740 |
| Genzyme Corporation May 23, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Lubbock, TX · in-kind | $917 |
| Genzyme Corporation May 23, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Lubbock, TX · in-kind | $581 |
| Genzyme Corporation May 23, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Lubbock, TX · in-kind | $276 |
| Genzyme Corporation May 23, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Lubbock, TX | $40.00 |
| Genzyme Corporation May 23, 2025 | Travel and Lodging QFITLIA · Hematology · travel to Lubbock, TX | $15.73 |
| Genzyme Corporation May 21, 2025 | Compensation for services other than consulting (speaking, faculty) QFITLIA · Hematology | $2,909 |
| Genentech, Inc. May 20, 2025 | Education Hemlibra · Hematology | $25.04 |
| Genzyme Corporation Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) CABLIVI · Hematology | $8,726 |
| Genzyme Corporation Apr 23, 2025 | Travel and Lodging CABLIVI · Hematology · travel to Fort Wayne, IN · in-kind | $1,408 |
| Genzyme Corporation Apr 5, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $10,388 |
| Genzyme Corporation Apr 5, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Richardson, TX · in-kind | $784 |
| Genzyme Corporation Apr 5, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Richardson, TX · in-kind | $310 |
| Genzyme Corporation Apr 5, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Richardson, TX · in-kind | $111 |
| Genzyme Corporation Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $3,324 |
| Novo Nordisk Inc Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $139 |
| Novo Nordisk Inc Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $418 |
| Novo Nordisk Inc Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $278 |
| Novo Nordisk Inc Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $278 |
| Genzyme Corporation Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $10,388 |
| Genzyme Corporation Feb 27, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Lubbock, TX · in-kind | $824 |
| Genzyme Corporation Feb 27, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Lubbock, TX · in-kind | $797 |
| Genzyme Corporation Feb 27, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Lubbock, TX · in-kind | $159 |
| Genzyme Corporation Feb 27, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Lubbock, TX | $28.00 |
| Genzyme Corporation Feb 19, 2025 | Compensation for services other than consulting (speaking, faculty) ALTUVIIIO · Hematology | $2,909 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 7 companies. The companies reported $104,837 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 Lenvatinib E7080,MK-7902 Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastati…
Merck Sharp & Dohme LLC - A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Merck Sharp & Dohme LLC - BMN 270-401
BioMarin Pharmaceutical Inc. - Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1
AstraZeneca Pharmaceuticals LP - An Open Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation - Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors
Boehringer Ingelheim Pharma GmbH & Co.kg - Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors
Boehringer Ingelheim Pharmaceuticals, Inc. - MRD Monotherapy, combination of VSV-GP w/ antiPD1
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.